Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 1;3(7):e207566.
doi: 10.1001/jamanetworkopen.2020.7566.

Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis

Lara Paracchini  1 , Chiara Pesenti  1 , Martina Delle Marchette  2 , Luca Beltrame  1 , Tommaso Bianchi  2 , Tommaso Grassi  2 , Alessandro Buda  2 , Fabio Landoni  2 , Lorenzo Ceppi  3 , Cristina Bosetti  1 , Mariachiara Paderno  2 , Marco Adorni  2 , Debora Vicini  2 , Patrizia Perego  4 , Biagio Eugenio Leone  4 , Maurizio D'Incalci  1 , Sergio Marchini  1 , Robert Fruscio  2
Affiliations

Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis

Lara Paracchini et al. JAMA Netw Open. .

Abstract

Importance: The low 5-year survival rate of women with high-grade serous epithelial ovarian cancer (HGS-EOC) is related to its late diagnosis; thus, improvement in diagnosis constitutes a crucial step to increase the curability of this disease.

Objective: To determine whether the presence of the clonal pathogenic TP53 variant detected in matched primary tumor biopsies can be identified in DNA purified from Papanicolaou test samples collected from women with HGS-EOC years before the diagnosis.

Design, setting, and participants: This cohort study was conducted among a single-center cohort of women with histologically confirmed diagnosis of HGS-EOC recruited at San Gerardo Hospital, Monza, Italy, from October 15, 2015, to January 4, 2019. Serial dilutions of DNA derived from tumor samples and DNA extracted from healthy women's Papanicolaou test samples were analyzed to define the sensitivity and specificity of droplet digital polymerase chain reaction assays designed to detect the TP53 variants identified in tumors. All available brush-based Papanicolaou test slides performed up to 6 years before diagnosis were investigated at the Mario Negri Institute, Milano, Italy. Data were analyzed from October 2018 to December 2019.

Main outcomes and measures: The presence of tumor pathogenic TP53 variants was assessed by the droplet digital polymerase chain reaction approach in DNA purified from Papanicolaou test samples obtained from the same patients before diagnosis during cervical cancer screenings.

Results: Among 17 included patients (median [interquartile range] age at diagnosis, 60 [53-69] years), Papanicolaou tests withdrawn before diagnosis presented tumor-matched TP53 variants in 11 patients (64%). In 2 patients for whom longitudinal Papanicolaou tests were available, including 1 patient with Papanicolaou tests from 25 and 49 months before diagnosis and 1 patient with Papanicolaou tests from 27 and 68 months before diagnosis, the TP53 clonal variant was detected at all time points.

Conclusions and relevance: These findings suggest that noninvasive early molecular diagnosis of HGS-EOC is potentially achievable through detection of TP53 clonal variants in the DNA purified from Papanicolaou tests performed during cervical cancer screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Paracchini and Pesenti reported receiving grant fellowships from Italian Association for Cancer Research. Dr Beltrame reported receiving personal fees from Eli Lilly outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Study Flow Diagram
For each locus-specific TP53 variant assay, droplet digital polymerase chain reaction experiments were performed with both positive and negative controls. Assay sensitivity was assessed on DNA purified from healthy donors. FFPE indicates formalin-fixed paraffin-embedded and HGS-EOC, high-grade serous epithelial ovarian cancer.
See this image and copyright information in PMC

References

    1. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615. doi: 10.1038/nature10166 - DOI - PMC - PubMed
    1. Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: a rereview of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol. 2016;35(1):48-55. doi: 10.1097/PGP.0000000000000207 - DOI - PMC - PubMed
    1. Labidi-Galy SI, Papp E, Hallberg D, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093. doi: 10.1038/s41467-017-00962-1 - DOI - PMC - PubMed
    1. Soong TR, Howitt BE, Miron A, et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the fallopian tube and disseminated high-grade serous carcinomas. J Pathol. 2018;246(3):344-351. doi: 10.1002/path.5145 - DOI - PubMed
    1. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5(167):167ra4. doi: 10.1126/scitranslmed.3004952 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances